Comprehensive safety assessment and therapeutic potential of Pediococcus acidilactici NMCC-B in attenuating arthritis progression
PLOS One · 2025
DOI: 10.1371/journal.pone.0324060 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Tayyaba Zulfiqar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan. Hauptthemen laut MEDLINE: Probiotics, Pediococcus acidilactici, Arthritis, Rheumatoid, Arthritis, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dysbiosis of gut microbiota and loss of gut-barrier integrity contribute to the development and severity of rheumatoid arthritis (RA). The available treatments pose a burden of major adverse effects and new treatment strategies are therefore the need of time. In this study, Pediococcus acidilactici NMCC-B (Probiotic) was evaluated for its safety and efficacy in complete Freund’s adjuvant (CFA)-induced mice model of RA. Mice were treated with either Escherichia coli (1 × 10 9 CFU/ml) or P. acidilactici NMCC-B (1 × 10 9 CFU/ml, 2 × 10 9 CFU/ml) to assess acute, sub-acute, and chronic toxicities. In RA model, mice were either pre-treated with daily dose of P. acidilactici NMCC-B or treated concurrently (day 1–day 27) or post-treated (day 28–day 42). P. acidilactici NMCC-B inhibited gut permeability, lessened joint inflammation, and ameliorated RA progression. No signs of toxicity, pathogenicity or bacterial translocation were observed in animals treated with probiotic. P. acidilactici NMCC-B also restored total body weight, attenuated inflammation, improved antioxidants, alleviated soft tissue swelling, bone damage, and the expression of IL-1β, NF-κB and TNF-α in paw tissue. Based on current findings, it is perceivable that P. acidilactici NMCC-B could be a promising candidate for the management of RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
- Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hail, Hail, Saudi Arabia.
- Department of Pharmacognosy, College of Pharmacy, Najran University, Najran, Saudi Arabia.
- Department of Pharmacognosy and Alternative Medicine, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia.
- Department of Pharmacology and Toxicology, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia.
- Department of Pharmacy Practice, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia.
ORCID-Profile: Amr S Abouzied, Muhammad Nasir Hayat Malik, Muhammad Usama Mazhar
Zitieren
APA
Zulfiqar, T., Tipu, M. K., Khan, M. T., Abouzied, A. S., Al Kazman, B. S. M., Alshammari, S. O., Alshammari, Q. A., Alshammari, A., Malik, M. N. H., Ali, A., Mazhar, M. U., & Jabeen, H. (2025). Comprehensive safety assessment and therapeutic potential of Pediococcus acidilactici NMCC-B in attenuating arthritis progression. PLOS One. https://doi.org/10.1371/journal.pone.0324060
Vancouver
Zulfiqar T, Tipu MK, Khan MT, Abouzied AS, Al Kazman BSM, Alshammari SO, et al. Comprehensive safety assessment and therapeutic potential of Pediococcus acidilactici NMCC-B in attenuating arthritis progression. PLOS One. 2025. doi:10.1371/journal.pone.0324060
BibTeX
@article{Zulfiqar2025,
author = {Zulfiqar, Tayyaba and Tipu, Muhammad Khalid and Khan, Muhammad Tariq and Abouzied, Amr S and Al Kazman, Bassam S M and Alshammari, Saud O and Alshammari, Qamar A and Alshammari, Abdulkarim and Malik, Muhammad Nasir Hayat and Ali, Amir and Mazhar, Muhammad Usama and Jabeen, Hafsa},
title = {Comprehensive safety assessment and therapeutic potential of Pediococcus acidilactici NMCC-B in attenuating arthritis progression},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0324060}
}
EUVIMED